Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: Relation with HIF2α and survival

Clinical and Experimental Metastasis

Volumn 29, Issue 1, 2012, Pages 11-17

  Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a   Bechrakis, Nikolaos E ^b   Willerding, Gregor ^c   St Charitoudis, Georgios ^c   Foerster, Michael H ^c   Gatter, Kevin C ^d   Harris, Adrian L ^d   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIF2 ; LDH5; Uveal melanomas; VEGF; VEGFR2

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN RECEPTOR 2; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UVEA MELANOMA; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; PHOSPHORYLATION; SURVIVAL; UVEA TUMOR;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; PHOSPHORYLATION; SURVIVAL ANALYSIS; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84856022107     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9424-6     Document Type: Article

References (33)

1. Lutz JM, Cree IA, Foss AJ (1999) Risk factors for intraocular melanoma and occupational exposure. Br J Ophthalmol 83: 1190-1193 (Pubitemid 29469128)
2. Gragoudas E, Li W et al (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120(12):1665-1671 (Pubitemid 36401801)
3. Bechrakis NE, Schmid E et al (2010) Proton beam irradiation of uveal melanomas of the posterior pole. Spektrum Augenheilkd 24:11-16
4. Bechrakis NE, Petousis V, Willerding G et al (2010) Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol. 94:460-466
5. Yang AS, Chapman PB (2009) The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 23: 583-597
6. Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62
7. Michaylira CZ, Nakagawa H (2006) Hypoxic microenvironment as a cradle for melanoma development and progression. Cancer Biol Ther 5:476-479 (Pubitemid 43765279)
8. Bedogni B, Powell MB (2009) Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 22:166-174
9. Giatromanolaki A, Sivridis E, Kouskoukis C et al (2003) Hypoxiainducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493-501 (Pubitemid 37266952)
10. Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4013-4604
11. Blancher C, Moore JW, Talks KL et al (2000) Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60:7106-7113 (Pubitemid 32059191)
12. Semenza GL, Jiang BH, Leung SW et al (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529-32537
13. Stewart M, Turley H, Cook N et al (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 43:33-39 (Pubitemid 36836585)
14. Edge SD, Byrd DR, Carducci MA, Compton CC (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
15. Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421 (Pubitemid 30626905)
16. Koukourakis MI, Giatromanolaki A, Sivridis E et al (2006) Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24:4301-4308 (Pubitemid 46630788)
17. Turley H, Scott PA, Watts VM et al (2005) Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186:313-318
18. Liu J, Qu R, Ogura M et al (2005) Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res 46: 93-102 (Pubitemid 40780154)
19. Victor N, Ivy A, Jiang BH et al (2006) Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis 23:87-96 (Pubitemid 44576782)
20. Liu Y, Tao J, Li Y, Yang J et al (2009) Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 17:269-277
21. el Filali M, Missotten GS, Maat W et al (2010) Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci 51: 2329-2337
22. Valencak J, Kittler H, Schmid K et al (2009) Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol 34:e962-e964
23. Young AC, Craven RA, Cohen D et al (2009) Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res 15:7582-7592
24. Steiner H, Berger AP, Godoy-Tundidor S et al (2004) An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 40:1066-1072 (Pubitemid 38496265)
25. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62:7203-7206
26. Kim SJ, Seo JH, Lee YJ et al (2005) Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. Oncology 68:204-211
27. Le A, Cooper CR, Gouw AM et al (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107:2037-2042
28. Boyd SR, Tan DS, de Souza L et al (2006)Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. 1. Br J Ophthalmol 86:440-447
29. Missotten GS, Notting IC, Schlingemann RO et al (2006) Vascular endothelial growth factor a in eyes with uveal melanoma. 1. Arch Ophthalmol 124:1428-1434 (Pubitemid 44537143)
30. Barak V, Pe'er J, Kalickman I et al (2011) VEGF as a biomarker for metastatic uveal melanoma in humans. 1. Curr Eye Res 36: 386-390
31. Flanigan J, Deshpande H, Gettinger S (2010) Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 4:237-243
32. Stadler WM, Cao D, Vogelzang NJ et al (2004) A randomized Phase II trial of the antiangiogenic agent SU5416 in hormonerefractory prostate cancer. Clin Cancer Res 10:3365-3370 (Pubitemid 38685441)
33. Banerjee S, A'Hern R, Detre S et al (2010) Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin Cancer Res 16:4178-4187